Yvonne L. Greenstreet
Biography
As Chief Executive Officer of Alnylam Pharmaceuticals, Inc., Yvonne L. Greenstreet leads a biotechnology company focused on the discovery, development, and commercialization of novel RNA interference (RNAi) therapeutics. Alnylam's innovative approach targets specific messenger RNA molecules that are responsible for disease, aiming to silence the genetic basis of various conditions. The company's pipeline spans both rare genetic diseases and more common, complex conditions, with a growing portfolio of approved medicines. Their work represents a significant advancement in precision medicine, offering new therapeutic possibilities for patients with limited or no treatment options. Greenstreet oversees the strategic direction and operational execution of Alnylam's mission to translate scientific breakthroughs into life-changing medicines for people worldwide.